跳至主要内容
临床试验/CTRI/2021/01/030796
CTRI/2021/01/030796
已完成
未知

Evaluation of Cellular Immunity in SARS-CoV-2 recovered subjects as an alternative to IgG testing - NI

Atrimed Biotech LLP0 个研究点目标入组 60 人待定

概览

阶段
未知
干预措施
未指定
疾病 / 适应症
未指定
发起方
Atrimed Biotech LLP
入组人数
60
状态
已完成
最后更新
3年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
2021年4月19日
最后更新
3年前
研究类型
Observational

研究者

发起方
Atrimed Biotech LLP

入排标准

入选标准

  • 1\) Both male and female adult populations aged from 18 to 60 years with background comorbidities such as Type II Diabetes mellitus(DM), hypertension(HTN), Bronchial asthma, Ischemic heart disease(IHD), cerebrovascular accidents(CVA), Thyroid disorders will be included in the study.
  • 2\) Convalescent, RTPCR negative for SARS\-CoV2 ( 2 weeks), IgG positive for SARS CoV2 , asymptomatic patients as determined by the principal investigator/ physician.
  • 3\) SARS CoV2 frontline workers are included as test subjects.
  • 4\) Non health care workers are included as control subjects. 5\) Volunteer is willing and able to comply with all the trial requirements. 5\) All volunteers obtained written informed consent form in English as well as native language, Kannada

排除标准

  • 1\) Patients with active COVID\-19 infection( PCR positive, IgM positive).
  • 2\) Known patients of HIV, Hepatitis\-B/C , H1N1\.
  • 3\) Pregnant and lactating women.
  • 4\) Patients with known autoimmune diseases on immuno\-suppressants and steroids.
  • 5\) Patients who have participated in another clinical trial within the previous 30 days.
  • 6\) Patient not willing to give informed consent form

结局指标

主要结局

未指定

相似试验